Amphastar Pharmaceuticals (AMPH) Cash from Investing Activities (2016 - 2026)

Amphastar Pharmaceuticals has reported Cash from Investing Activities over the past 13 years, most recently at -$60.6 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 69.77% year-over-year to -$60.6 million; the TTM value through Dec 2025 reached -$70.3 million, up 43.7%, while the annual FY2025 figure was -$70.3 million, 43.7% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$60.6 million at Amphastar Pharmaceuticals, down from -$19.6 million in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $15.2 million in Q1 2024 and troughed at -$508.6 million in Q2 2023.
  • A 5-year average of -$45.3 million and a median of -$10.5 million in 2021 define the central range for Cash from Investing Activities.
  • Biggest five-year swings in Cash from Investing Activities: crashed 44899.56% in 2023 and later skyrocketed 340.6% in 2024.
  • Year by year, Cash from Investing Activities stood at -$12.0 million in 2021, then skyrocketed by 98.08% to -$229000.0 in 2022, then crashed by 44899.56% to -$103.0 million in 2023, then skyrocketed by 65.38% to -$35.7 million in 2024, then tumbled by 69.77% to -$60.6 million in 2025.
  • Business Quant data shows Cash from Investing Activities for AMPH at -$60.6 million in Q4 2025, -$19.6 million in Q3 2025, and -$625000.0 in Q2 2025.